869 related articles for article (PubMed ID: 27092773)
1. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.
Zhang M; Hutter G; Kahn SA; Azad TD; Gholamin S; Xu CY; Liu J; Achrol AS; Richard C; Sommerkamp P; Schoen MK; McCracken MN; Majeti R; Weissman I; Mitra SS; Cheshier SH
PLoS One; 2016; 11(4):e0153550. PubMed ID: 27092773
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration.
Zhang Y; Sime W; Juhas M; Sjölander A
Eur J Cancer; 2013 Oct; 49(15):3320-34. PubMed ID: 23810249
[TBL] [Abstract][Full Text] [Related]
3. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.
Kim D; Wang J; Willingham SB; Martin R; Wernig G; Weissman IL
Leukemia; 2012 Dec; 26(12):2538-45. PubMed ID: 22648449
[TBL] [Abstract][Full Text] [Related]
6. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.
Yoshida K; Tsujimoto H; Matsumura K; Kinoshita M; Takahata R; Matsumoto Y; Hiraki S; Ono S; Seki S; Yamamoto J; Hase K
Cancer Med; 2015 Sep; 4(9):1322-33. PubMed ID: 26077800
[TBL] [Abstract][Full Text] [Related]
7. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
8. Spleen-derived macrophages are readily polarized into classically activated (M1) or alternatively activated (M2) states.
Mulder R; Banete A; Basta S
Immunobiology; 2014 Oct; 219(10):737-45. PubMed ID: 24954891
[TBL] [Abstract][Full Text] [Related]
9. A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature.
Mignogna C; Signorelli F; Vismara MF; Zeppa P; Camastra C; Barni T; Donato G; Di Vito A
Pathol Res Pract; 2016 Jun; 212(6):491-9. PubMed ID: 27101800
[TBL] [Abstract][Full Text] [Related]
10. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth.
Cao M; Yan H; Han X; Weng L; Wei Q; Sun X; Lu W; Wei Q; Ye J; Cai X; Hu C; Yin X; Cao P
J Immunother Cancer; 2019 Nov; 7(1):326. PubMed ID: 31775862
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma.
Zhang X; Wang S; Nan Y; Fan J; Chen W; Luan J; Wang Y; Liang Y; Li S; Tian W; Ju D
Appl Microbiol Biotechnol; 2018 Aug; 102(15):6503-6513. PubMed ID: 29754163
[TBL] [Abstract][Full Text] [Related]
12. TIGIT blockade repolarizes AML-associated TIGIT
Brauneck F; Fischer B; Witt M; Muschhammer J; Oelrich J; da Costa Avelar PH; Tsoka S; Bullinger L; Seubert E; Smit DJ; Bokemeyer C; Ackermann C; Wellbrock J; Haag F; Fiedler W
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549780
[TBL] [Abstract][Full Text] [Related]
13. Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.
Wang Y; Yin C; Feng L; Wang C; Sheng G
Genet Mol Res; 2015 May; 14(2):5630-41. PubMed ID: 26125761
[TBL] [Abstract][Full Text] [Related]
14. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
15. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
[TBL] [Abstract][Full Text] [Related]
16. Suppressed expression of homotypic multinucleation, extracellular domains of CD172α (SIRP-α) and CD47 (IAP) receptors in TAMs upregulated by Hsp70-peptide complex in Dalton's lymphoma.
Gautam PK; Acharya A
Scand J Immunol; 2014 Jul; 80(1):22-35. PubMed ID: 24684700
[TBL] [Abstract][Full Text] [Related]
17. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Lin GHY; Chai V; Lee V; Dodge K; Truong T; Wong M; Johnson LD; Linderoth E; Pang X; Winston J; Petrova PS; Uger RA; Viller NN
PLoS One; 2017; 12(10):e0187262. PubMed ID: 29084248
[TBL] [Abstract][Full Text] [Related]
18. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype.
Xue N; Zhou Q; Ji M; Jin J; Lai F; Chen J; Zhang M; Jia J; Yang H; Zhang J; Li W; Jiang J; Chen X
Sci Rep; 2017 Jan; 7():39011. PubMed ID: 28045028
[TBL] [Abstract][Full Text] [Related]
19. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
20. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin.
Jaguin M; Houlbert N; Fardel O; Lecureur V
Cell Immunol; 2013 Jan; 281(1):51-61. PubMed ID: 23454681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]